GSK slides 6% after US CDC narrows scope of RSV shots By Reuters
(Reuters) - GlaxoSmithKline shares fell more than 6% on Thursday, a day after the U.S. public health agency narrowed its recommendation for the use of all respiratory syncytial virus (RSV) vaccines and suspended recommending their use in…